Funds › Sabby Management, LLC
Sabby Management, LLC
13F for Q3 2026, filed Nov 13, 2026. 14 positions worth $9.0M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Sabby Management, LLC in the latest 13F quarter?
Using 13F.ai, how has Sabby Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Sabby Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | TOYO TOYO Co., Ltd | 482,175 | $2.1M | 23.3% | -4.3% | 13F ↗ |
| 2 | PN PN Smart Energy Limited | 269,000 | $737.1K | 8.2% | New | 13F ↗ |
| 3 | YXT Yxt.com Group Holding Ltd · ADR | 286,085 | $646.6K | 7.2% | New | 13F ↗ |
| 4 | ZVRA Zevra Therapeutics, Inc. | 57,850 | $634.6K | 7.0% | New | 13F ↗ |
| 5 | CRVO CervoMed Inc. | 199,678 | $593.0K | 6.6% | -19.8% | 13F ↗ |
| 6 | APVO Aptevo Therapeutics Inc. | 232,692 | $423.5K | 4.7% | New | 13F ↗ |
| 7 | iShares Tr Etf | 1,000 | $277.9K | 3.1% | New | 13F ↗ |
| 8 | PAVS Paranovus Entertainment Technology Ltd. | 64,671 | $260.6K | 2.9% | -14.3% | 13F ↗ |
| 9 | SNES SenesTech, Inc. | 313,132 | $211.9K | 2.3% | +121% | 13F ↗ |
| 10 | CPHI China Pharma Holdings, Inc. | 308,360 | $202.6K | 2.2% | New | 13F ↗ |
| 11 | CANF Can-Fite Biopharma Ltd · ADR | 85,207 | $187.5K | 2.1% | New | 13F ↗ |
| 12 | BCTXL BriaCell Therapeutics Corp. · *W Exp 01/15/203 | 136,365 | $158.2K | 1.8% | -28.4% | 13F ↗ |
| 13 | SIDU Sidus Space, Inc. | 85,905 | $155.5K | 1.7% | +98.0% | 13F ↗ |
| 14 | Revelation Biosciences Inc Com 2025 | 126,915 | $103.7K | 1.1% | -39.7% | 13F ↗ |
Changes since Q2 2026
7 new, 2 added to, 5 trimmed, 9 exited, 0 unchanged. By estimated dollars.
New positions (7)
| PN PN Smart Energy Limited | 269,000 | New | $737.1K |
| YXT Yxt.com Group Holding Ltd · ADR | 286,085 | New | $646.6K |
| ZVRA Zevra Therapeutics, Inc. | 57,850 | New | $634.6K |
| APVO Aptevo Therapeutics Inc. | 232,692 | New | $423.5K |
| iShares Tr Etf | 1,000 | New | $277.9K |
| CPHI China Pharma Holdings, Inc. | 308,360 | New | $202.6K |
| CANF Can-Fite Biopharma Ltd · ADR | 85,207 | New | $187.5K |
Trimmed (5)
Exited (9)
| SPY State Street SPDR S&P 500 ETF Trust · Trust units | 5,500 | Exited | -$4.1M |
| FAMI Farmmi, Inc. | 3.52M | Exited | -$840.3K |
| TPST Tempest Therapeutics, Inc. | 511,286 | Exited | -$567.5K |
| Bioaffinity Technologies Inc | 365,647 | Exited | -$296.9K |
| CREG Smart Powerr Corp. | 127,774 | Exited | -$263.2K |
| BCTX BriaCell Therapeutics Corp. | 80,721 | Exited | -$261.5K |
| INM InMed Pharmaceuticals Inc. | 44,970 | Exited | -$69.7K |
| NUWE Nuwellis, Inc. | 16,372 | Exited | -$49.9K |
| BCTXZ BriaCell Therapeutics Corp. · *W Exp 99/99/999 | 120,802 | Exited | -$11.5K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 21 | $9.0M | Current | SEC ↗ |
| Q2 2026 | Aug 14, 2026 | 13F-HR | 23 | $110.5M | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 28 | $45.1M | Current | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | 13F-HR | 33 | $69.5M | Current | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | 13F-HR | 39 | $86.4M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 43 | $55.1M | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 46 | $34.0M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer